OLYMPIA, Wash. — Washington will receive millions of dollars following a settlement with eight drug companies.
The companies are said to have “worsened the nationwide opioid crisis,” according to the Washington Attorney General’s Office.
The state will receive $16 million of the $720 million settlement.
Attorneys general from several states worked to secure the agreement. The settlement includes the following companies:
- Mylan (now part of Viatris): $284,447,916 paid over nine years
- Hikma: $95,818,293 paid over one to four years
- Amneal: $71,751,010 paid over 10 years
- Apotex: $63,682,369 paid in a single year
- Indivior: $38,022,450 paid over four years
- Sun: $30,992,087 paid over one to four years
- Alvogen: $18,680,162 paid in a single year
- Zydus: $14,859,220 paid in a single year
In addition to abatement payments, several settlements allow states to receive free pharmaceutical products or cash.
Seven of the companies are barred from promoting or marketing opioids or opioid products. These companies make or sell any product containing more than 40 milligrams of oxycodone per pill because of the settlement. They must also implement monitoring and reporting systems for suspicious orders.
Indivior has agreed to stop manufacturing and selling opioid products for the next 10 years while still selling and marketing medications that treat opioid use disorders.
The final amount Washington state will receive depends on the participation of eligible counties and cities in the settlement.
Washington has received $1.3 billion through various opioid settlements since 2022.
©2025 Cox Media Group
